PTC THERAPEUTICS, INC. (PTCT) Stock
7 of the hedge funds AlphaScala tracks reported PTCT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $126.35M. Company insiders reported 0 open-market buys and 27 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own PTCT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.55M | $126.35M | -6% |
| Citadel Ken Griffin | 748K | $61.00M | +94% |
| Renaissance Technologies Jim Simons (founder) | 724K | $59.02M | +36% |
| Marshall Wace | 705K | $57.49M | +53% |
| Millennium Management Israel Englander | 46K | $3.79M | NEW |
| Hussman Investment Trust John Hussman | 32K | $2.57M | NEW |
| Blackstone | 8K | $682.2K | -19% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are PTC THERAPEUTICS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Schmertzler Michael | Director | SELL | 2.1K | $126K |
| Oct 14, 26 | Schmertzler Michael | Director | SELL | 382 | $23K |
| Oct 9, 26 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 192 | $12K |
| Oct 7, 26 | Schmertzler Michael | Director | SELL | 2.4K | $155K |
| Oct 7, 26 | Schmertzler Michael | Director | SELL | 53 | $3K |
| Oct 6, 26 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 435 | $28K |
| Oct 5, 26 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 1.6K | $105K |
| Sep 30, 26 | Steele Glenn Jr Md Phd | Director | SELL | 12.0K | $782K |
| Sep 17, 26 | Schmertzler Michael | Director | SELL | 9.6K | $653K |
| Sep 17, 26 | Schmertzler Michael | Director | SELL | 376 | $26K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →PTCT price chart
Powered by TradingViewWhat does PTC THERAPEUTICS, INC. do?
Ptc Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for patients living with rare disorders, particularly orphan diseases affecting children and adults. The company specializes in orally administered small molecule drugs and gene therapies that target post-transcriptional control mechanisms to regulate gene expression. Its approved products include Translarna for nonsense mutation Duchenne muscular dystrophy, Emflaza for Duchenne muscular dystrophy, Upstaza for aromatic L-amino acid decarboxylase deficiency, a central nervous system disorder, and commercialization rights for WAYLIVRA in Latin America. PTC also collaborates on Evrysdi for spinal muscular atrophy. The company's pipeline features investigational therapies such as sepiapterin for phenylketonuria and vatiquinone for Friedreich's ataxia, alongside platforms addressing inflammation, ferroptosis, and Huntington's disease. As a patient-centric organization headquartered in South Plainfield, New Jersey since 1998, Ptc Therapeutics Inc. leverages scientific expertise and global commercial infrastructure to deliver transformative treatments for diseases with high unmet medical needs.